Healthcare Contract Manufacturing Industry Overview
The global healthcare contract manufacturing market size was valued at USD 211.9 billion in 2021 and is projected to expand at a compound annual growth rate (CAGR) of 9.6% from 2022 to 2030. An increase in offshoring, especially in emerging countries, and the changing regulatory landscape, are the prominent trends currently present in the market. Pharmaceutical and medical device companies are outsourcing low-end services to third parties (CMOs) to reduce the overall cost of production and speed up the time to market of products. This trend is expected to contribute to the growth of the contract manufacturing market in the foreseeable future. COVID-19 brought in unparalleled demand for diagnostic tests, Personal Protective Equipment (PPE), ventilators, and other critical medical supplies. COVID-19 has had a major impact on the supply-demand gap, with a 1,000 to 2,000-fold increase for PPE products, raw material shortages increased by over 10% thereby pushing the by more than 100% in 2020.
The COVID-19 pandemic has forced many pharmaceutical and medical device companies to increase the manufacturing of drugs and medical devices needed by infected patients worldwide. The U.S. FDA has observed that over 60% of FDA-regulated products imported from China are medical devices, making U.S. medical device industry highly dependent on China’s supply chain. Medical device manufacturers are facing severe supply bottlenecks, which will ultimately reduce the company’s scope of revenue generation.
Gather more insights about the market drivers, restraints, and growth of the Global Healthcare Contract Manufacturing market
The presence of end-to-end service providers that are engaged in providing value-added services for an integrated or risk-sharing business model is expected to boost the market growth. Pharmaceutical and medical device companies are outsourcing manufacturing activities to CMOs to reduce their manufacturing footprint. It allows manufacturers to be more dynamic and cost-effective in their manufacturing process.
In addition, factors such as the increasing prevalence of noninvasive surgical procedures are driving the demand for pharmaceutical drugs and medical devices. To meet such increased demand, OEMs are outsourcing the manufacturing of non-core manufacturing activities as it assists them in reducing labor costs, freeing up capital, increasing worker productivity, and improving manufacturing lead times. For many large, medium and small pharma firms, outsourcing turns out to be an economic option, as fixed costs for manufacturing biologics products account for around 60–70% of the Cost of goods sold (COGS) and cannot be avoided even during idle conditions.
Therefore, the use of multi-product facilities to produce biologics has been proven economically efficient and safe as there is negligible to no risk with respect to product carryover, thereby supporting market growth. Since the medical device industry is highly regulated, making rapid changes in the supply chain may not be manageable. Medical device manufacturers distributing products in the U.S. are not required to report actual or potential supply chain shortages to the FDA. Despite this, the FDA is actively addressing potential shortages in the medical device supply chain. Some of the products facing shortage are aluminum products, integrated circuits, lithium-ion batteries, and special components, including pneumatic fittings, black body radiation source, & platinum.
This has created an unprecedented demand for the manufacturing of active pharmaceutical ingredients (APIs), finished doses, and medical devices in order to maintain supply. According to Medical Product Outsourcing, manufacturers expect outsourcing to yield cost savings and faster time to market. According to various reputed tabloids, companies are expected to outsource more work, based on a 2020 Global Managed Services Report. This report has performed a survey with 1,250 executives across 29 countries, which stated that 45% of organizations will outsource more in the coming years. However, the limited production capacity of CMOs may pose a major challenge restraining the market growth.
Browse through Grand View Research's Medical Devices Industry Research Reports.
Nutraceutical Contract Manufacturing Services Market - The nutraceutical contract manufacturing services market size was estimated at USD 133.34 billion in 2022 and is expected to expand at a compound annual growth rate (CAGR) of 12.04% from 2023 to 2030.
Medical Device Outsourcing Market - The global medical device outsourcing market was valued at USD 117.5 billion in 2022 and is expected to grow at a compound annual growth rate (CAGR) of 12.1% from 2023 to 2030.
Healthcare Contract Manufacturing Market Segmentation
Grand View Research has segmented the global healthcare contract manufacturing market based on type and region:
Healthcare Contract Manufacturing Type Outlook (Revenue, USD Billion, 2017 - 2030)
- Medical Device
- Pharmaceutical
Healthcare Contract Manufacturing End use Outlook (Revenue, USD Billion, 2017 - 2030)
- Medical Device Companies
- Pharmaceutical Companies
- Biopharmaceutical Companies
Healthcare Contract Manufacturing Regional Outlook (Revenue, USD Billion, 2017 - 2030)
- North America
- Europe
- Asia Pacific
- Latin America
- Middle East & Africa
Market Share Insights
February 2020: Integer Holdings Corporation acquired Inomec, an Israel-based company. The acquisition is likely to provide Integer with an R&D & sales center in Israel and would add catheter design, clinical, & pilot manufacturing capabilities to its portfolio.
October 2018: Nordson Corporation acquired Clada Medical Devices, a design & development firm mainly focused on balloon catheters. This enhanced the company’s design & development capabilities, which further supports the company’s position as a prominent contract manufacturer for OEMs across the interventional & surgical device landscape.
Key Companies profiled:
Some prominent players in the global healthcare contract manufacturing market include:
- Nordson Corporation
- Integer Holdings Corporation
- Jabil Inc.
- Viant Technology LLC
- FLEX LTD.
- Celestica Inc.
- Sanmina Corporation
- Plexus Corp.
- Phillips-Medisize
- West Pharmaceutical Services, Inc.
- Synecco
- Catalent, Inc.
- Thermo Fisher Scientific Inc.
- Recipharm
- Boehringer Ingelheim International GmbH
- Lonza
- Samsung Biologics
- WuXi AppTec
- FUJIFILM Diosynth Biotechnologies
- Cambrex Corporation
Order a free sample PDF of the Healthcare Contract Manufacturing Market Intelligence Study, published by Grand View Research.
No comments:
Post a Comment